Tag: LLC

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

EINDHOVEN, The Netherlands, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ:NXPI) (together with its subsidiaries, “NXP”) announced today the pricing of an offering by its subsidiaries NXP B.V., NXP Funding LLC and NXP USA, Inc. (together, the “Issuers”) of $500,000,000 aggregate principal amount of 4.300% senior unsecured notes due 2028 (the “2028 Notes”), $300,000,000 aggregate principal amount of 4.850% senior unsecured notes due 2032 (the “2032 Notes”) and $700,000,000 aggregate principal amount of 5.250% senior unsecured notes due 2035 (the “2035 Notes” and, collectively with the 2028 Notes and the 2032 Notes, the “Notes”).

With Three-Year Revenue Growth of 7260.85%, This Marks Maximus' 1st Time on the List

With Three-Year Revenue Growth of 7260.85%, This Marks Maximus' 1st Time on the List

BOHEMIA, N.Y., Aug. 12, 2025 /PRNewswire/ -- Nature's Truth and Natural Vitality are hitting the road this August with their most ambitious Back to School...

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Grocery TV, an in-store retail media platform, today announced its ranking of No. 1793 (No. 154 in Advertising,...

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

With Three-Year Revenue Growth of 81 Percent, This Marks Air2O's First Time on the List  NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Inc., the leading media...

SACRAMENTO, Calif., Aug. 12, 2025 /PRNewswire/ -- Straine Dental Management is proud to announce it has made the prestigious Inc. 5000 list once again,...

BOSSCAT Ranks No. 1493 With Revenue Growth of 291 Percent From 2021 to 2024 CHARLESTON, S.C., Aug. 12, 2025 /PRNewswire/ -- BOSSCAT Home Services and...

Juvent joins the 2025 Inc. 5000, ranking #757 with 552% growth over 3 years, for its Micro-Impact Platform, which improves mobility, pain, and wellness.